Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study

被引:32
作者
SeyedAlinaghi, SeyedAhmad [1 ]
Abbasian, Ladan [1 ,2 ]
Solduzian, Mohammad [3 ]
Ayoobi Yazdi, Niloofar [4 ]
Jafari, Fatemeh [2 ]
Adibimehr, Alireza [2 ]
Farahani, Aazam [2 ]
Salami Khaneshan, Arezoo [2 ]
Ebrahimi Alavijeh, Parvaneh [2 ]
Jahani, Zahra [2 ]
Karimian, Elnaz [2 ]
Ahmadinejad, Zahra [2 ]
Khalili, Hossein [5 ]
Seifi, Arash [2 ]
Ghiasvand, Fereshteh [2 ]
Ghaderkhani, Sara [2 ]
Rasoolinejad, Mehrnaz [2 ]
机构
[1] Univ Tehran Med Sci, Iranian Inst Reduct High Risk Behav, Iranian Res Ctr HIV AIDS, Tehran, Iran
[2] Univ Tehran Med Sci, Imam Khomeini Hosp, Dept Infect Dis, Blvd Keshavarz, Tehran 1419733141, Iran
[3] Tabriz Univ Med Sci, Dept Clin Pharm, Fac Pharm, Golgasht St, Tabriz 5166414766, Iran
[4] Univ Tehran Med Sci, Imam Khomeini Hosp, Dept Radiol, Tehran, Iran
[5] Univ Tehran Med Sci, Dept Clin Pharm, Imam Khomeini Hosp Complex, Tehran, Iran
关键词
COVID-19; Recovery; Time; Predictors; Dyspnea; Comorbidities; CLINICAL-COURSE; CORONAVIRUS; SARS-COV-2; HOSPITALS; WUHAN; DEATH; RISK;
D O I
10.1186/s40001-021-00513-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The clinical course of COVID-19 may vary significantly. The presence of comorbidities prolongs the recovery time. The recovery in patients with mild-to-moderate symptoms might take 10 days, while in those with a critical illness or immunocompromised status could take 15 days. Considering the lack of data about predictors that could affect the recovery time, we conducted this study to identify them. Methods This cross-sectional study was implemented in the COVID-19 clinic of a teaching and referral university hospital in Tehran. Patients with the highly suggestive symptoms who had computed tomography (CT) imaging results with typical findings of COVID-19 or positive results of reverse transcriptase-polymerase chain reaction (RT-PCR) were enrolled in the study. Inpatient and outpatient COVID-19 participants were followed up by regular visits or phone calls, and the recovery period was recorded. Results A total of 478 patients were enrolled. The mean age of patients was 54.11 +/- 5.65 years, and 44.2% were female. The median time to recovery was 13.5 days (IQR: 9). Although in the bivariate analysis, multiple factors, including hypertension, fever, diabetes mellitus, gender, and admission location, significantly contributed to prolonging the recovery period, in multivariate analysis, only dyspnea had a significant association with this variable (p = 0.02, the adjusted OR of 2.05; 95% CI 1.12-3.75). Conclusion This study supports that dyspnea is a predictor of recovery time. It seems like optimal management of the comorbidities plays the most crucial role in recovery from COVID-19.
引用
收藏
页数:10
相关论文
共 51 条
[1]   COVID-19 Pandemic: Cardiovascular Complications and Future Implications [J].
Bandyopadhyay, Dhrubajyoti ;
Akhtar, Tauseef ;
Hajra, Adrija ;
Gupta, Manasvi ;
Das, Avash ;
Chakraborty, Sandipan ;
Pal, Ipsita ;
Patel, Neelkumar ;
Amgai, Birendra ;
Ghosh, Raktim K. ;
Fonarow, Gregg C. ;
Lavie, Carl J. ;
Naidu, Srihari S. .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (04) :311-324
[2]   Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19 [J].
Bao, Jinfeng ;
Li, Chenxi ;
Zhang, Kai ;
Kang, Haiquan ;
Chen, Wensen ;
Gu, Bing .
CLINICA CHIMICA ACTA, 2020, 509 :180-194
[3]   COVID-19 pandemic and its recovery time of patients in India: A pilot study [J].
Barman, Manash Pratim ;
Rahman, Tousifur ;
Bora, Krishnarjun ;
Borgohain, Chandan .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (05) :1205-1211
[4]   Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes Systematic Review and Meta-analysis [J].
Cano, Edison J. ;
Fuentes, Xavier Fonseca ;
Campioli, Cristina Corsini ;
O'Horo, John C. ;
Abu Saleh, Omar ;
Odeyemi, Yewande ;
Yadav, Hemang ;
Temesgen, Zelalem .
CHEST, 2021, 159 (03) :1019-1040
[5]   Persistent Symptoms in Patients After Acute COVID-19 [J].
Carfi, Angelo ;
Bernabei, Roberto ;
Landi, Francesco .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (06) :603-605
[6]   Clinical progression of patients with COVID-19 in Shanghai, China [J].
Chen, Jun ;
Qi, Tangkai ;
Liu, Li ;
Ling, Yun ;
Qian, Zhiping ;
Li, Tao ;
Li, Feng ;
Xu, Qingnian ;
Zhang, Yuyi ;
Xu, Shuibao ;
Song, Zhigang ;
Zeng, Yigang ;
Shen, Yinzhong ;
Shi, Yuxin ;
Zhu, Tongyu ;
Lu, Hongzhou .
JOURNAL OF INFECTION, 2020, 80 (05) :E1-E6
[7]   Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study [J].
Cummings, Matthew J. ;
Baldwin, Matthew R. ;
Abrams, Darryl ;
Jacobson, Samuel D. ;
Meyer, Benjamin J. ;
Balough, Elizabeth M. ;
Aaron, Justin G. ;
Claassen, Jan ;
Rabbani, LeRoy E. ;
Hastie, Jonathan ;
Hochman, Beth R. ;
Salazar-Schicchi, John ;
Yip, Natalie H. ;
Brodie, Daniel ;
O'Donnell, Max R. .
LANCET, 2020, 395 (10239) :1763-1770
[8]   Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? [J].
Dallocchio, R. N. ;
Dessi, A. ;
De Vito, A. ;
Delogu, G. ;
Serra, P. A. ;
Madeddu, G. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (05) :2435-2448
[9]   Epidemiology of COVID-19 and Predictors of Recovery in the Republic of Korea [J].
Das, Ashis Kumar ;
Gopalan, Saji Saraswathy .
PULMONARY MEDICINE, 2020, 2020
[10]   Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection. A real-life experience [J].
De Vito, A. ;
Geremia, N. ;
Princic, E. ;
Fanelli, C. ;
Napodano, C. M. Panu ;
Muredda, A. A. ;
Fiore, V ;
Maida, I ;
Fois, A. G. ;
Babudieri, S. ;
Madeddu, G. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (01) :523-526